Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficacy in animal models of BC of a recombinant BCG known as BCG-disA-OE that releases the small molecule STING agoni...
Alternative Titles
Full title
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2902166332
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2902166332
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/2023.12.15.571740
How to access this item
https://www.proquest.com/docview/2902166332?pq-origsite=primo&accountid=13902
